Liquiritigenin pharmacokinetics in a rat model of diabetes mellitus induced by streptozotocin: Greater formation of glucuronides in the liver, especially M2, due to increased hepatic uridine 5′-diphosphoglucuronic acid level

Metabolism: Clinical and Experimental

Volumn 59, Issue 10, 2010, Pages 1472-1480

  Kang, Hee E ^a   Sohn, Se I ^b   Baek, Seung R ^b   Lee, Jee W ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Daewoong Pharmaceutical Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONIDE; LIQUIRITIGENIN; URIDINE DIPHOSPHATE GLUCURONIC ACID; ANTIINFLAMMATORY AGENT; FLAVANONE DERIVATIVE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD LEVEL; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INDUCED DISEASE; DRUG TRANSFORMATION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; LIVER; LIVER PROTECTION; MALE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; ANIMAL; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL DIABETES MELLITUS; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DRUG EVALUATION, PRECLINICAL; FLAVANONES; GLUCURONIDES; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; URIDINE DIPHOSPHATE GLUCURONIC ACID;

EID: 77956972235     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.01.012     Document Type: Article

References (33)

1. Shimamura H., Nakai S., Yamamoto K., Hitomi N., and Yumioka E. Biliary and urinary metabolites of liquiritigenin in rats Jpn J Pharmacogn 44 1990 265 268
2. Shimamura H., Suzuki H., Hanano M., Suzuki A., and Sugiyama Y. Identification of tissues responsible for the conjugative metabolism of liquiritigenin in rats: an analysis based on metabolite kinetics Biol Pharm Bull 16 1993 899 907
3. Kang H.E., Cho Y.K., and Jung H.Y. Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect Xenobiotica 39 2009 465 475
4. Kang H.E., Jung H.Y., and Cho Y.K. Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs, and animal scale-up J Pharm Sci 98 2009 4327 4342
5. Kim S.C., Byun S.H., Yang C.H., Kim C.Y., Kim J.W., and Kim S.G. Cytoprotective effects of Glycyrrhizae radix extract and its active component liquiritigenin against cadmium-induced toxicity (effects on bad translocation and cytochrome c-mediated PARP cleavage) Toxicology 197 2004 239 251
6. Kim Y.W., Ki S.H., and Lee J.R. Liquiritigenin, an aglycone of liquiritin in Glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sulfoximine Chem Biol Interact 161 2006 125 138
7. Kim Y.W., Kang H.E., and Lee M.G. Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic transporters and phase-II enzymes Am J Physiol Gastrointest Liver Physiol 296 2009 G372 381
8. Vanni E., Abate M.L., and Gentilcore E. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C Hepatology 50 2009 697 706
9. Imaeda K., and Nojiri S. Hepato-biliary and pancreatic disease and osteodystrophy Clin Calcium 19 2009 1275 1280
10. Watanabe S., Yaginuma R., Ikejima K., and Miyazaki A. Liver diseases and metabolic syndrome J Gastroenterol 43 2008 509 518
11. Prashanth M., Ganesh H.K., and Vima M.V. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus J Assoc Physicians India 57 2009 205 210
12. Watkins J.B. 3rd, and Sanders R.A. Diabetes mellitus-induced alterations of hepatobiliary function Pharmacol Rev 47 1995 1 23
13. Lee J.H., and Lee M.G. Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin Pharm Res 25 2008 1915 1924
14. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 1976 248 254
15. Watkins J.B., and Klaassen C.D. Determination of hepatic uridine 5′-diphosphoglucuronic acid concentration by conjugation with diethylstilbestrol J Pharmacol Methods 7 1982 145 151
16. Fisher M.B., Campanale K., Ackermann B.L., VandenBranden M., and Wrighton S.A. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin Drug Metab Dispos 28 2000 560 566
17. Duggleby R.G. Analysis of enzyme progress curves by nonlinear regression Methods Enzymol 249 1995 61 90
18. Yamamura N., Imura-Miyoshi K., and Naganuma H. Panipenum, a carbapenem antibiotic, increases the level of hepatic UDP-glucuronic acid in rats Drug Metab Dispos 28 2000 1484 1486
19. Boudinot F.D., and Jusko W.J. Fluid shifts and other factors affecting plasma protein-binding of prednisolone by equilibrium dialysis J Pharm Sci 73 1984 774 780
20. Eie S., and Guentert T.W. Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer J Pharm Sci 71 1982 127 128
21. Mitruka B.M., and Rawnsley H.M. Clinical biomedical and hematological reference values in normal experimental animals and normal humans 2nd ed 1981 Masson Publishing New York
22. Kang H.E., Choi K.Y., and Lee M.G. Determination of an agent for the inflammatory liver disease, liquiritigenin, in rat plasma, urine, and various tissue homogenates by high-performance liquid chromatography Proceedings of the Spring International Convention of the Pharmaceutical Society of Korea, International Convention Center, Jeju, South Korea, 2008; April 30-May 3 2008 342 (Abstract)
23. Almási A., Fischer E., and Perjési P. A simple and rapid ion-pair HPLC method for simultaneous quantitation of 4-nitrophenol and its glucuronide and sulfate conjugates J Biochem Biophys Methods 69 2006 43 50
24. Gibaldi M., and Perrier D. Pharmacokinetics second ed 1982 Marcel-Dekker New York
25. Chiou W.L. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve J Pharmacokinet Biopharm 6 1978 539 546
26. Wilkinson G.R., and Shand D.G. A physiological approach to hepatic drug clearance Clin Pharmacol Ther 18 1975 377 390
27. Sato H., Terasaki T., Okumura K., and Tsuji A. Effect of receptor up-regulation on insulin pharmacokinetics in streptozotocin-treated diabetic rats Pharm Res 8 1991 563 569
28. Miettinen T.A., and Leskinen E. Glucuronic acid pathway W.H. Fishman, Metabolic conjugation and metabolic hydrolysis 1970 Academic Press New York 157 237
29. Eacho P.I., Sweeny D., and Weiner M. Conjugation of p-nitroanisole and p-nitrophenol in hepatocytes isolated from streptozotocin diabetic rats J Pharmacol Exp Ther 218 1981 34 40
30. Winegrad A.I., and Burden C.L. l-Xylulose metabolism in diabetes mellitus N Engl J Med 274 1966 298 305
31. Anderson J.W. Metabolic abnormalities contributing to diabetic complications. I. Glucose metabolism in insulin-insensitive pathways Am J Clin Nutr 28 1975 273 280
32. Sochor M., Baquer N.Z., and McLean P. Regulation of pathways of glucose metabolism in kidney: effect of experimental diabetes on the activity of the pentose phosphate pathway and glucuronate-xylulose pathway Arch Biochem Biophys 198 1979 632 646
33. Chorné R., Mendoza C., Pisanty J., Castro N., and Loría A. Increase of conjugated bilirubin in diabetics Rev Invest Clin 46 1994 237 239